COMPANY PROFILE

Exobiosphere

Explore full profile

Platform leveraging microgravity to accelerate drug discovery and develop novel therapeutics for improved human health

Esch-sur-Alzette, LuxembourgFounded 2024Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2025

Headcount <100 Current team size

Total funding $0–10M Disclosed equity funding

Unlock exact values

About Exobiosphere

EXOBIOSPHERE, founded in 2024 in Luxembourg, aims to transform the drug discovery process by utilizing the unique advantages of microgravity environments. The company provides a platform that unlocks new insights into cellular behaviors not observable under Earth's gravity. These insights are harnessed to accelerate the development of novel therapeutics, ultimately improving human health both on Earth and in space. EXOBIOSPHERE serves clients in the pharmaceutical, skincare, and nutrition sectors, offering an efficient, dependable, and safe gateway for space-based research. The company's business model revolves around providing the tools and insights necessary for clients to develop new, effective therapies more rapidly and cost-effectively than traditional methods. Revenue is generated through service fees for access to their microgravity research platform and associated support services.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: Esch-sur-Alzette, Luxembourg
Employees: 27
Open positions: None listed
Dealroom signal: 88.1/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Space Tech, Biotech and Pharma, In-Space Research, In-Space Operations, Space Upstream, Techbio, Space DT
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Exobiosphere.

See all news

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANT✓Other financing	Aug 2026	$1.1M	—	Ministry of the Economy Luxembourg	↗
SUPPORT PROGRAM✓Other financing	May 2026	$83K	—	Cassini Business Accelerator · EUSPA · CASSINI Initiative	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Exobiosphere website traffic

Latest recorded traffic for Exobiosphere is 380 monthly website visits, down 77.6% over the last three months. Exobiosphere's team grew 68.8% over the past year.

Latest monthly visits380 3-month web change-77.6% 1-year team growth+68.8%

Monthly website visitsMar 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBioOrbitBioOrbit is space manufacturing company developing hardware for the large-scale crystallisation of protein drugs	London, United Kingdom	Operational	20	$13M	$52M
YUYuriA space biotech company that uses the microgravity environment of space to develop and manufacture superior biotech products	Meckenbeuren, Germany	Operational
SBSibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs	Bresso, Italy	Operational
NENeuraspaceDeveloper of an advanced AI-powered space debris monitoring and satellite collision avoidance platform	Coimbra, Portugal	Operational
TCThe Exploration CompanyDemocratises space exploration, for space and non-space industries	Planegg, Germany	Operational
DSDeep Trait S.A.Biotechnology company with a mission to address fundamental questions of food supply, health care and life itself with artificial intelligence	Aschersleben, Germany	Operational
IRIRUBISResponsible for developing innovative processes for manufacturing using spectroscopy	Munich, Germany	Operational
BIBioXplorDeveloping a computational network pharmacology platform to match optimal drug combinations to the right patients	Dublin, Ireland	Operational